vTv Therapeutics (NASDAQ:VTVT) Stock Bumped Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a sell rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

Other analysts have also recently issued research reports about the stock. HC Wainwright reduced their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Weiss Ratings cut shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Zacks Research raised shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Finally, BTIG Research reiterated a “buy” rating and set a $57.00 price target on shares of vTv Therapeutics in a research report on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.83.

vTv Therapeutics Stock Performance

vTv Therapeutics stock opened at $21.03 on Friday. vTv Therapeutics has a one year low of $20.56 and a one year high of $44.00. The business has a fifty day moving average of $29.22 and a two-hundred day moving average of $33.23. The company has a market cap of $82.86 million, a P/E ratio of -22.86 and a beta of 0.28.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.15. Sell-side analysts predict that vTv Therapeutics will post -2.35 EPS for the current year.

Institutional Investors Weigh In On vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 114.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,360 shares of the biotechnology company’s stock after acquiring an additional 2,860 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in vTv Therapeutics were worth $161,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.